Bronchiectasis is a significant chronic health problem with major morbidity, mortality, and economic costs. However, despite the large burden of disease, much of the treatment for bronchiectasis is not guided by high-quality randomized controlled data but extrapolated from studies in patients with cystic fibrosis. Thankfully, in the past few years, we have had several high-quality publications in noncystic fibrosis bronchiectasis in the areas of nebulized antibiotic therapy and chronic oral macrolide therapy. This review focuses on these recent publications as they significantly change the approach toward patients with bronchiectasis, particularly those who have frequent exacerbations. © 2014 by Lippincott Williams and Wilkins.